Your browser doesn't support javascript.
Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus.
Warren, Travis K; Kane, Christopher D; Wells, Jay; Stuthman, Kelly S; Van Tongeren, Sean A; Garza, Nicole L; Donnelly, Ginger; Steffens, Jesse; Gomba, Laura; Weidner, Jessica M; Norris, Sarah; Zeng, Xiankun; Bannister, Roy; Cihlar, Tomas; Bavari, Sina; Porter, Danielle P; Iversen, Patrick L.
  • Warren TK; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
  • Kane CD; The Geneva Foundation, Tacoma, WA, 98402, USA.
  • Wells J; Laulima Government Solutions, Integrated Research Facility NIAID/NIH, Fort Detrick, Frederick, MD, 21702, USA.
  • Stuthman KS; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
  • Van Tongeren SA; National Cancer Institute, Frederick, MD, 21702, USA.
  • Garza NL; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
  • Donnelly G; The Geneva Foundation, Tacoma, WA, 98402, USA.
  • Steffens J; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
  • Gomba L; The Geneva Foundation, Tacoma, WA, 98402, USA.
  • Weidner JM; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
  • Norris S; The Geneva Foundation, Tacoma, WA, 98402, USA.
  • Zeng X; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
  • Bannister R; The Geneva Foundation, Tacoma, WA, 98402, USA.
  • Cihlar T; SARS-CoV-2 Virology Core, LVD/NIAID/NIH, Bethesda, MD, 20892, USA.
  • Bavari S; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
  • Porter DP; The Geneva Foundation, Tacoma, WA, 98402, USA.
  • Iversen PL; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Sci Rep ; 11(1): 19458, 2021 09 30.
Article in English | MEDLINE | ID: covidwho-1447326
ABSTRACT
Efficacious therapeutics for Ebola virus disease are in great demand. Ebola virus infections mediated by mucosal exposure, and aerosolization in particular, present a novel challenge due to nontypical massive early infection of respiratory lymphoid tissues. We performed a randomized and blinded study to compare outcomes from vehicle-treated and remdesivir-treated rhesus monkeys in a lethal model of infection resulting from aerosolized Ebola virus exposure. Remdesivir treatment initiated 4 days after exposure was associated with a significant survival benefit, significant reduction in serum viral titer, and improvements in clinical pathology biomarker levels and lung histology compared to vehicle treatment. These observations indicate that remdesivir may have value in countering aerosol-induced Ebola virus disease.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Hemorrhagic Fever, Ebola / Alanine / Ebolavirus Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Animals Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-98971-0

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Hemorrhagic Fever, Ebola / Alanine / Ebolavirus Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Animals Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-98971-0